OQROGet OQRO Pro
Insider trade

Enliven Therapeutics (ELVN)CHIEF SCIENTIFIC OFFICER sold ~$98K

Joseph P Lyssikatos, CHIEF SCIENTIFIC OFFICER at Enliven Therapeutics, sold ~$98K of Enliven Therapeutics shares.

~$98K
Approx. value · 5,000 sh @ $19.62
948K
Holds after · shares reported
Traded
Aug 19, 2025
Filed
Aug 21, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Jun 20, 2025InsiderOfficer sold ~$267K of ELVN shares in the open market
  2. Jun 27, 2025Insider · 1 personInsiders: 2 sales (~$68K)
  3. Jul 7, 2025Insider · 1 personInsiders: 2 sales (~$132K)
  4. Jul 10, 2025InsiderCFO sold ~$23K of ELVN shares in the open market
  5. Jul 17, 2025Insider · 1 personInsiders: 3 sales (~$282K)
  6. Jul 21, 2025Insider · 1 personInsiders: 2 sales (~$279K)
  7. Jul 28, 2025Insider · 1 personInsiders: 2 sales (~$67K)
  8. Aug 7, 2025Insider · 1 personInsiders: 2 sales (~$122K)
  9. Aug 19, 2025 · this disclosureInsiderOfficer sold ~$98K of ELVN shares in the open market

What came next

  1. Aug 20, 2025InsiderCEO sold ~$30K of ELVN shares in the open market
  2. Aug 21, 2025InsiderOfficer sold ~$150K of ELVN shares in the open market
  3. Aug 27, 2025InsiderCFO sold ~$67K of ELVN shares in the open market
  4. Sep 8, 2025InsiderOfficer sold ~$135K of ELVN shares in the open market
  5. Sep 17, 2025InsiderCEO sold ~$95K of ELVN shares in the open market
  6. Sep 19, 2025Insider · 2 peopleInsiders: 3 sales (~$156K)
  7. Sep 23, 2025Insider · 2 peopleInsiders: 2 sales (~$86K)
  8. Sep 26, 2025Insider · 2 peopleInsiders: 2 sales (~$155K)
  9. Nov 12, 2025Company filing · Form 8-K · ResultsReported its results
  10. Nov 12, 2025Company filing · Form 8-K · ResultsReported its results
  11. Dec 9, 2025Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On December 11, 2025, Enliven Therapeutics, Inc. (the “ Company ”) announced the appointment of Richard Fair as the Company’s President and Chief Executive Officer and as a member of the board of directors (the “ Board ”) of the Company, effective as of December 11, 2025 (the “ Effective Date ”).”
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Enliven Therapeutics

For Enliven Therapeutics, OQRO holds 1 insider filing (SEC Form 4 or Form 144) and 6 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ELVN page.

Other recent filings by Joseph P Lyssikatos, CHIEF SCIENTIFIC OFFICER

The full history of Joseph P Lyssikatos, CHIEF SCIENTIFIC OFFICER is on the profile page.

How this filing works

Other disclosures at Enliven Therapeutics

Everything OQRO holds on this company is on its ELVN page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data